Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFC-723 is a proprietary skin‑lightening cosmetic ingredient developed by Sirona Biochem as part of its fluorinated carbohydrate-based depigmenting platform. Preclinical safety testing on reconstituted human epithelium showed that TFC-723 is non-irritant, non-phototoxic under UVA irradiation, and non-genotoxic, and it is reported to be chemically stable and not to release hydroquinone, addressing safety concerns associated with traditional hydroquinone-based agents.[1][4] Although detailed molecular mechanism and formal therapeutic indications have not been disclosed publicly, it is positioned as a next‑generation topical skin‑lightening/brightening agent for incorporation into cosmetic and dermatologic formulations via licensing to commercial partners.[1][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TFC-723.